Paul Peter Tak - 26 Jul 2021 Form 3 Insider Report for Candel Therapeutics, Inc. (CADL)

Role
President & CEO, Director
Signature
/s/ Paul Peter Tak
Issuer symbol
CADL
Transactions as of
26 Jul 2021
Net transactions value
$0
Form type
3
Filing time
26 Jul 2021, 21:22:33 UTC
Next filing
02 Aug 2021
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
holding CADL Stock Option (Right to Buy) 26 Jul 2021 Common Stock 296,144 $1.55 Direct F1
holding CADL Stock Option (Right to Buy) 26 Jul 2021 Common Stock 1,776,868 $1.55 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 This option shall vest (if at all) if a specified stock price following the Issuer's initial public offering is obtained on or prior to September 12, 2023.
F2 25% of this option vested and became exercisable on October 10, 2020, with a remaining 25% vesting on September 14, 2021, and the remainder vesting in 36 substantially equal monthly installments thereafter.